Intravascular Lithotripsy Market (2026 - 2033)

Intravascular Lithotripsy Market Summary

The global intravascular lithotripsy market size was valued at USD 1.1 billion in 2025 and is projected to grow from USD 1.3 billion in 2026 to USD 2.9 billion by 2033, at a CAGR of 11.5% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 79.2% in 2025. Market growth is driven by the increasing prevalence of calcified coronary and peripheral artery disease, rising adoption of intravascular lithotripsy for the treatment of severely calcified lesions, and growing demand for advanced vessel preparation technologies that facilitate complex cardiovascular interventions.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Market Dynamics

The intravascular lithotripsy market is driven by the rising prevalence of coronary artery disease, increasing cases of calcified arterial lesions, and growing demand for minimally invasive cardiovascular procedures. Technological advancements in lithotripsy balloon catheters are improving the treatment of severely calcified lesions and supporting adoption in percutaneous coronary intervention (PCI). However, high device costs, limited access to advanced catheterization facilities, and stringent regulatory requirements may restrain market growth. Expanding clinical evidence, increasing physician awareness, and the adoption of intravascular lithotripsy in peripheral arterial interventions are expected to create growth opportunities.

Market Concentration & Characteristics

The chart below illustrates the relationship between industry concentration, characteristics, and participants. The X-axis represents the level of market concentration, ranging from low to high. The Y-axis represents various market characteristics, including industry competition, degree of innovation, level of mergers & acquisition activities, regulatory impact, product substitutes, and regional expansion.

The market demonstrates a high degree of innovation, with manufacturers developing advanced technologies to improve the treatment of severely calcified coronary lesions. For instance, in May 2026, Boston Scientific’s Seismiq 4CE Coronary IVL Catheter demonstrated promising results in a first-in-human study involving 41 patients, achieving a 97.4% device success rate and 89.5% procedural success rate, with no reported vessel perforations, abrupt closures, or no-reflow events following IVL. The Seismiq platform uses laser energy to generate acoustic pressure waves that target and fracture vascular calcium, highlighting ongoing innovation in IVL technology for complex coronary interventions.

To learn more about this report, Download Free Sample Report

M&A activity in the market has increased as major medical device companies seek to expand their peripheral vascular portfolios and gain access to next-generation calcium-modification technologies. For instance, in May 2026, Stryker completed the acquisition of Amplitude Vascular Systems (AVS), a medical technology company developing a next-generation IVL platform for treating complex peripheral arterial disease. AVS’s technology uses pulsed CO₂-generated pressure waves delivered through an IVL balloon catheter to fracture calcium and improve luminal gain, while being designed to enhance catheter deliverability, treatment speed, and therapy efficiency.

“This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial. By integrating AVS’s innovative CO₂-generated pressure wave technology with Stryker’s scale and resources, we are well-positioned to deliver solutions that support physicians and patient outcomes.” -Kevin Lobo, Chair and CEO, Stryker.

Regulations have a moderate impact on the IVL market because regulatory requirements affect the speed at which new technologies enter the market and increase manufacturers’ development and compliance costs. In the U.S., the FDA’s 510(k) premarket notification pathway requires IVL manufacturers to demonstrate substantial equivalence to a legally marketed device before commercialization, which lengthen product development and approval timelines. However, regulatory clearance also supports physician confidence, patient safety, and broader clinical adoption, thereby influencing market growth.

Product expansion in the market is high, as manufacturers are actively introducing next-generation catheters with improved deliverability, lesion-crossing, repositioning, and treatment capabilities. For instance, in May 2026, Johnson & Johnson globally launched the Shockwave C2 Aero Coronary IVL Catheter, featuring improved deliverability, enhanced lesion crossing, and repositioning capabilities for treating calcified coronary artery disease, thereby expanding its existing IVL product portfolio.

“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices. That enhanced deliverability and efficiency can change IVL use and expand its role in treatment algorithms. By continuing to address real unmet physician needs like deliverability, crossability and repositioning, Johnson & Johnson is pushing expectations for what the technology can achieve in complex PCI procedures.” -Margaret McEntegart, M.D., Ph.D., Director of Complex Percutaneous Coronary Intervention Program at Columbia University Medical Center/New York-Presbyterian Hospital.

Analyst Perspective

The intravascular lithotripsy market is characterized by increasing competition between established medtech companies with broad cardiovascular portfolios and emerging players focused on differentiated calcium-modification technologies. Established companies are strengthening their positions through product innovation, clinical validation, geographic expansion, physician education, and integration of IVL into coronary and peripheral vascular treatment pathways, while emerging players are pursuing novel catheter designs, energy-delivery mechanisms, and targeted applications to address unmet procedural needs. Competitive intensity is expected to increase as companies seek to improve catheter deliverability, lesion crossing, treatment efficiency, and clinical outcomes while expanding IVL adoption across complex calcified lesions. Strategic acquisitions, partnerships, clinical studies, and new product launches are further contributing to technology advancement and portfolio expansion.

Product Insights

The intravascular lithotripsy catheters segment accounted for the largest share of around 98.6% in 2025, primarily due to the increasing use of IVL catheters for modifying calcified lesions and improving vessel expansion during endovascular procedures. The segment is also benefiting from technological advancements that enable treatment of increasingly complex lesions. For instance, in September 2025, Johnson & Johnson launched the Shockwave Javelin Peripheral IVL Catheter in Europe, a novel Forward IVL platform designed to modify extremely narrowed or occluded calcified peripheral lesions. The launch expanded the application of IVL technology in patients with peripheral artery disease (PAD), a condition affecting more than 230 million people globally and approximately 15 million people aged 45 years and older in Europe. The expansion is particularly relevant to patients with chronic limb-threatening ischemia (CLTI), the most advanced form of PAD, which affects nearly 25 million people globally and is associated with substantial risks of major amputation and mortality.

The intravascular lithotripsy accessories segment is the second-largest segment in 2025, driven by the increasing use of supporting components required for the effective delivery of IVL therapy. These accessories include IVL generators, connectors, cables, and other procedural components that support catheter operation during lithotripsy procedures. The growing adoption of IVL for coronary and peripheral artery disease, particularly for complex and heavily calcified lesions, is increasing demand for compatible accessories. In addition, the expansion of IVL platforms into peripheral vascular applications and more challenging anatomies is broadening the utilization of these supporting components. The increasing volume of IVL procedures and the need for reliable, compatible equipment further support segment growth, while continued innovation in IVL systems is expected to create additional demand for associated accessories.

Application Insights

The calcified coronary artery disease segment held the largest market share of 77.4% in 2025. The segment growth is driven by the high prevalence of coronary calcification among patients undergoing percutaneous coronary intervention (PCI) and the increasing use of IVL to modify calcified lesions before stent placement. According to a study published by NCBI in February 2025, calcified coronary artery disease is a common clinical finding and is visible angiographically in approximately 25-30% of patients presenting for PCI. The substantial prevalence of coronary calcification, combined with the challenges associated with treating heavily calcified lesions using conventional angioplasty, is supporting the adoption of IVL technology in coronary interventions.

The calcified peripheral artery disease segment is expected to register the fastest growth during the forecast period, supported by the high prevalence of peripheral artery disease (PAD) and increasing demand for minimally invasive treatment of heavily calcified peripheral lesions. According to data published by the American College of Cardiology in October 2024, PAD affects more than 200 million people globally and accounts for approximately 10-15% of the population over 50 years of age; prevalence is estimated at 3-10% among adults in Western populations and can exceed 20% in Asia and other developing regions. The substantial patient population, combined with the challenges associated with treating severely calcified and narrowed peripheral vessels, is expected to increase the adoption of IVL. Furthermore, the development of next-generation peripheral IVL technologies capable of addressing difficult-to-cross and occlusive calcified lesions is expected to further support segment growth.

End Use Insights

The cardiac catheterization laboratories segment dominated the market with a revenue share of 64.8% in 2025. Cardiac catheterization laboratories are equipped to perform complex coronary interventions and provide the controlled procedural environment required for intravascular imaging, lesion preparation, calcium modification, and stent placement. The increasing integration of IVL systems into catheterization laboratory workflows, together with the expansion of facilities performing complex PCI and the growing availability of coronary IVL catheters, is supporting the segment's leading position. In addition, improvements in catheter deliverability and compatibility with existing catheterization laboratory equipment are facilitating broader adoption of IVL within these specialized end-use settings.

To learn more about this report, Download Free Sample Report

The ambulatory surgical centers segment is anticipated to grow at the fastest CAGR over the forecast period, driven by the continued migration of peripheral vascular procedures from hospitals to lower-cost outpatient settings, shorter recovery times, and expanding reimbursement support for IVL procedures. In the U.S., the 2024 CMS OPPS/ASC final rule established payment pathways for IVL procedures involving the iliac, femoral, and popliteal arteries, supporting the adoption of peripheral IVL in ASCs. The broader ASC environment is also expanding rapidly. For instance, Vizient’s 2026 Impact of Change forecast projects ASC procedure volume to grow by 24% over the next decade, supported by advances in minimally invasive technologies, payer demand for lower-cost care settings, consumer preference for outpatient care, and the continued expansion of procedures eligible for ambulatory surgery.

“Ambulatory surgery will remain one of healthcare’s fastest-growing care settings. The growth will be driven by advances in minimally invasive technology, consumer expectations, payer demand for lower-cost care settings and continued expansion of procedures eligible for ambulatory surgery.”

-Karyl Kopaskie, principal of Vizient strategy intelligence.

Regional Insights

North America dominated the intravascular lithotripsy (IVL) market, accounting for 79.2% of global revenue in 2025. The region’s growth is supported by advanced cardiovascular care infrastructure, and high adoption of minimally invasive vascular interventions. The region has a large and well-established network of hospitals, cardiac catheterization laboratories, and specialized vascular centers, providing a strong clinical base for IVL procedures. In addition, the increasing prevalence of coronary and peripheral artery disease, particularly among the aging population, is contributing to demand for calcium-modification technologies. For instance, according to data published by Cardiac Advisor in February 2024, approximately 1 in 20 U.S. adults, or around 5% of Americans aged 20 years and older, live with coronary artery disease, highlighting the substantial patient population requiring advanced interventions for coronary disease and supporting demand for technologies such as IVL.

To learn more about this report, Download Free Sample Report

U.S. Intravascular Lithotripsy Market Trends

The U.S. dominated the North America market in 2025, supported by the country’s advanced cardiovascular care infrastructure, high adoption of minimally invasive vascular procedures, and increasing use of calcium-modification technologies for treating complex coronary and peripheral lesions. The presence of established interventional cardiology centers, leading IVL manufacturers, and a well-developed regulatory framework has facilitated the commercialization and adoption of IVL technologies. For instance, in July 2026, the U.S. FDA granted clearance to Shockwave Medical’s E8 Peripheral IVL Catheter, expanding the range of IVL technologies available for peripheral vascular applications in the U.S. market.

Europe Intravascular Lithotripsy Market Trends

The intravascular lithotripsy market in Europe is expected to grow significantly over the forecast period. The availability of new technologies with differentiated energy-delivery approaches is broadening the competitive landscape and providing physicians with additional options for calcium modification. For instance, in April 2025, Elixir Medical announced the EU MDR CE Mark approval and commercial launch of its LithiX Hertz Contact (HC) IVL System in Europe for the treatment of moderate to severely calcified coronary artery lesions. The first procedures were performed at leading cardiovascular centers in Italy, France, and Germany, demonstrating early clinical adoption across multiple European markets. The continued introduction of innovative IVL systems, expansion of commercial availability, and adoption across specialized cardiovascular centers are expected to support the growth of the European IVL market.

“With LithiX we created the first mechanical IVL platform capable of treating broad calcified lesion morphologies with great final outcomes, while minimizing injury to adjacent non-calcified vessel.” - Motasim Sirhan, CEO of Elixir Medical.

The Germany intravascular lithotripsy market is expected to represent a significant market for IVL in Europe, supported by its extensive interventional cardiology infrastructure and established capacity for complex cardiovascular procedures. According to the European Society of Cardiology's available country-level data, the country had 28.59 interventional cardiologists per million people, reflecting a substantial specialist base capable of performing advanced catheter-based interventions. Moreover, the country’s established PCI infrastructure provides an important clinical base for the adoption of IVL, particularly as coronary calcification becomes increasingly recognized as a challenge during complex interventions.

The UK intravascular lithotripsy market is witnessing growth. Increasing clinical acceptance of the technology within the National Health Service (NHS), growing evidence from real-world clinical practice, and efforts to evaluate IVL across broader peripheral vascular applications is driving the market in the country. For instance, in February 2025, NICE published guidance concluding that IVL are used as an option for treating calcified coronary arteries during PCI with standard arrangements for clinical governance, consent, and audit. This regulatory and clinical recognition supports the integration of IVL into UK cardiovascular care pathways.

Asia Pacific Intravascular Lithotripsy Market Trends

The Asia Pacific is expected to register the fastest growth rate over the forecast period. The region is witnessing greater clinical validation of IVL systems, which is improving physician familiarity with calcium-modification techniques and supporting their integration into coronary intervention procedures. For instance, in December 2025, the prospective, multicenter LEAD-FIM study conducted across 11 sites in China enrolled 184 patients with severely calcified coronary lesions and reported a procedural success rate of 96.7%, significantly exceeding the prespecified performance goal of 85.0%. The study also reported 85.3% overall stent expansion at the site of maximum calcification and no serious device-related adverse events, demonstrating the potential of IVL to facilitate stent delivery and optimize stent expansion in severely calcified lesions. Such clinical evidence, together with expanding interventional cardiology capabilities and increasing adoption of locally developed IVL technologies across Asia Pacific, is expected to support regional market growth.

The China intravascular lithotripsy market holds the largest market share in 2025. The expansion of cardiovascular intervention infrastructure and growing availability of locally developed medical devices are supporting broader access to advanced coronary treatment technologies. For instance, in February 2025, MicroPort RotaPace received market approval in China for the TomaHawk Integrated Coronary IVL System, comprising a disposable coronary IVL balloon catheter and treatment device for complex coronary artery disease. The system was designed to simplify IVL procedures, reduce operational complexity, and facilitate the treatment of moderate-to-severe calcified lesions, supporting the wider clinical application of IVL technology in China.

The India intravascular lithotripsy market is anticipated to register significant growth during the forecast period, driven by the increasing adoption of advanced coronary intervention techniques and growing clinical experience in treating heavily calcified coronary lesions. The availability of real-world evidence from Indian cardiac centers is strengthening physician confidence in IVL and supporting its use as a vessel-preparation technology during complex PCI. For instance, results from the Shock India Registry, presented in the Journal of the American College of Cardiology in October 2024, evaluated 1,053 patients with calcified coronary artery disease across 53 sites in India. In the OCT-guided subgroup, the primary efficacy endpoint was achieved in 89% of patients, while device and angiographic success reached 100%; stent expansion at the maximum calcium site was 102.63 ± 23.71%. The registry also reported no cases of perforation, severe dissection, abrupt vessel closure, slow flow, or no-reflow, providing real-world evidence supporting the safety and effectiveness of IVL for complex calcified coronary interventions in India.

Latin America Intravascular Lithotripsy Market Trends

The Latin America region is expected to witness significant growth over the forecast period, supported by the increasing adoption of advanced interventional cardiology technologies and growing demand for effective vessel preparation in patients with heavily calcified coronary lesions. The expansion of specialized catheter-based cardiovascular procedures and the introduction of new IVL technologies are improving access to calcium-modification solutions and broadening treatment options for complex PCI.

The Brazil intravascular lithotripsy market is anticipated to register significant growth during the forecast period. The growing involvement of leading medical device manufacturers in the region is strengthening the availability of innovative IVL systems and supporting physician familiarity with technology. For instance, in June 2026, Lepu Medical launched its Vesscrack Coronary IVL Balloon Dilatation Catheter in Brazil at the Instituto Dante Pazzanese de Cardiologia, a leading cardiovascular center. The system features high navigability, nine diameter options, and a next-generation balloon design delivering up to 120 pulses, supporting treatment of complex calcified coronary lesions and optimal stent expansion.

Middle East And Africa Intravascular Lithotripsy Market Trends

The Middle East and Africa intravascular lithotripsy market is anticipated to witness significant growth over the forecast period. The development of specialized cardiovascular centers and increasing availability of complex PCI capabilities are improving access to advanced lesion-preparation technologies across the region. In addition, growing clinical evidence from healthcare institutions is strengthening physician confidence in IVL and demonstrating its applicability to both native coronary lesions and in-stent restenosis. For instance, a retrospective study conducted in March 2026 at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia, involving 45 patients treated with IVL between January 2019 and January 2025, reported successful reperfusion in all patients, with 100% achieving final TIMI 3 flow and no in-hospital major adverse cardiovascular events (MACE). Such evidence supports the clinical utility of IVL for severely calcified coronary lesions and contribute to broader adoption of the technology across the region.

The intravascular lithotripsy market in South Africa is witnessing growth. Cost efficiency is particularly important in the South Africa healthcare environment, where reducing procedure-related expenditure while maintaining clinical effectiveness can support the adoption of innovative technologies. For instance, a pilot study conducted by Discovery in South Africa evaluated Shockwave Intravascular Lithotripsy and reported that the technology demonstrated a favorable safety profile while reducing costs associated with traditional disposable devices used for calcium modification. Such evidence highlighting both clinical and economic benefits support broader adoption of IVL.

Key Intravascular Lithotripsy Company Insights

Key participants in the intravascular lithotripsy industry are focusing on devising innovative business growth strategies, such as expanding their product portfolios, partnerships and collaborations, mergers and acquisitions, and expanding their business footprints.

Key Intravascular Lithotripsy Companies

The following key companies have been profiledfor this study on the intravascular lithotripsy market.

• Johnson & Johnson MedTech (Shockwave)

• Boston Scientific

• Elixir Medical

• MicroPort Scientific

• Sonosemi Medical

• Spectrumedics Medical

• Lepu Medical

• Zhonghui Medical

• FastWave Medical

Product Pipeline Analysis, By Stage

The intravascular lithotripsy market pipeline is advancing through the development of next-generation systems targeting complex coronary, carotid, and peripheral calcified lesions. Key players are progressing through pivotal clinical studies and first-in-human evaluations, focusing on improving device deliverability, lesion modification, and treatment options for patients with heavily calcified arteries.

New IVL Platforms Emerging Globally

The introduction of advanced IVL platforms designed to improve device deliverability, lesion crossing, and calcium modification in complex peripheral and coronary artery disease. Key developments include new product launches, regulatory clearances, and geographic expansion by major players, supporting broader clinical adoption and strengthening competition in the global market.

Recent Developments

• In May 2026, Johnson & Johnson launched the Shockwave C2 Aero Coronary IVL Catheter, a next-generation device designed to improve deliverability, lesion crossing, and balloon repositioning during treatment of calcified coronary artery disease. The launch expanded the company’s IVL portfolio and enabled physicians to address a broader range of complex calcified coronary lesions using the established Shockwave IVL mechanism of action.

• In May 2026, Boston Scientific presented late-breaking data from the FRACTURE trial at EuroPCR, evaluating its Seismiq 4CE Coronary IVL Catheter in 420 patients with severely calcified coronary artery disease. The study reported a 93.3% rate of freedom from major adverse cardiac events at 30 days and a 93.7% procedural success rate, exceeding the study’s predefined targets. The findings supported the potential of the Seismiq 4CE platform as a new coronary IVL option for complex PCI, although the device had not yet received FDA approval at the time of the report.

• In October 2024, MedAxiom partnered with Shockwave Medical to educate cardiologists and cardiology programs on the benefits and clinical applications of intravascular lithotripsy (IVL). The collaboration aimed to support greater awareness and adoption of IVL for treating severely calcified coronary and peripheral artery disease.

Global Intravascular Lithotripsy Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global intravascular lithotripsy market report based on product, application, end use, and region.

To learn more about this report, Download Free Sample Report

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Intravascular Lithotripsy Systems

  • Intravascular Lithotripsy Catheters

  • Intravascular Lithotripsy Generators

  • Intravascular Lithotripsy Accessories

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Calcified Coronary Artery Disease

  • Calcified Peripheral Artery Disease

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Cardiac Catheterization Laboratories

  • Ambulatory Surgical Centers

  • Specialty Vascular Clinics

  • Other Healthcare Facilities

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The intravascular lithotripsy market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each intravascular lithotripsy segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations